Sanofi (NASDAQ: SNY) has shared the promising interim results from a Phase 1/2 study for its mRNA-based COVID-19 vaccine candidate. This is the greatest milestone for the firm as Sanofi has made progress in its struggles in the fight against the COVID-19 pandemic with its adjuvanted recombinant protein candidate vaccine, developed in collaboration with GSK.
The preliminary data from Phase 1/2 demonstrated that neutralizing antibody seroconversion in 91% to 100% of study contributors, two weeks after a second dose, across all 3 dosages examined. Sanofi has witnessed no safety concern and the tolerability profile is analogous to that of other unmodified mRNA COVID-19 vaccines.
Furthermore, Sanofi has also disclosed that it is also aiming 2022 commencement of its clinical studies for an influenza vaccine with modified mRNA, Sanofi introduced a Phase 1 clinical study in June 2021 assessing an mRNA-based investigational vaccine against seasonal influenza. In addition, SNY also working on its pledge to making a significant contribution to current global public health urgencies, with the supply of half a billion doses of approved vaccines.
Likewise, the firm is the only company utilizing its worldwide production capacity and expertise for the supply of three different authorized COVID-19 vaccines from BioNTech / Pfizer, Moderna, and Johnson & Johnson. It is not surprising that the production teams on three industrial sites of the firm in France, Germany, and the U.S. are prepared, with 30 million doses distributed so far.
As far as the collaboration of Sanofi and GSK concern, Sanofi offers its recombinant antigen and GSK gives its pandemic adjuvant, both founded vaccine platforms that have remained successful against influenza. The recombinant technology integrated with GSK’s adjuvant is meant to deliver benefits of stability at temperatures that are used for day-to-day vaccines.